6th February 2024

Pharmanovia appoints new regional manager – Spain, Portugal and France

For business and pharma trade media only

  • Harco Giling has been announced as new regional manager, with more than 15 years’ experience within the pharmaceutical sector.
  • This new role addresses aims to better support customers and patients in these markets.

BASILDON, UK, 30 January 2024

Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has appointment Harco Giling as Regional Manager Spain, Portugal and France.

In his role, Harco will be responsible for establishing a stronger local presence, responsible for maintaining strong connections with payors, stakeholders and customers across the region.

Before joining Pharmanovia, Harco was Vice President, Europe for Shilpa Medicare. Prior to this he was with Intas Pharmaceuticals for over eight years, where he was responsible for the European Key-accounts. Harco’s substantial experience includes contract management and strategic projects.

Harco holds a bachelor’s degree from Saxion University of Applied Sciences and a MBA from EADA Business School, before starting his career in the pharmaceutical industry.

Commenting, James Burt, CEO, Pharmanovia: “We are very pleased to have Harco in this role, he brings a wealth of knowledge and experience and will help support the strong growth we’ve seen in these markets.”

-Ends-

Notes to editors

For further information, please contact:

About Pharmanovia

Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.

We do this by rediscovering, repurposing or re-engineering established medicines to improve patient outcomes and experiences as well as identifying new chemical entities that complement our existing portfolio to address unmet need.

With a diverse and growing team in over 160 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.